|
Striking
the US market
Too many players and too much competition make the US a bad
pitch to bat on. However, Indian companies are not ready to
leave the field. Katya Naidu discovers why the US market retains
its supremacy.
Upfront
Similar
yet different
Once again the industry came together, discussed and disbursed.
But though this is similar, it was different this time. The
theme was catalysing sustainable growth and leadership through
innovation. The venue too was different but the industry in
discussion was the same.
The
Asian invasion
Speaking at an interactive meeting with a high powered business
delegation from Indonesia organised by FICCI, His Excellency
M Jusuf Kalla, Hon'ble Vice-President of Indonesia said, "I
am confident that in the near future China, India and Indonesia
could be the leading economies of the world and Asia, the
development hub."
Creating
a stir
The Indo-US workshop on cytometry with practicals in otherwise
dry theory sessions proved to be very knowledgeble to the
attendees. Moreover, the topics were discussed at a micro
level. The attendees included students who were graduates
and post-graduates or even those who have already got themselves
a job in the wellbeing industry.
Upcoming
Events
Waters
establishes worldwide distribution network
Waters Corporation announced the worldwide distribution of
the YMC HPLC analytical and preparative column lines, a highly
respected series of products that Waters has distributed since
1997.
Ranbaxy
and GSK extend R&D deal
Ranbaxy Laboratories and GlaxoSmithKline signed a new multiyear
R&D agreement, expanding the strategic alliance already
in place since 2003.
Actavis
acquires API division
Actavis Group, the international generic pharmaceuticals company,
announced that it has acquired the API division of Sanmar
Specialty Chemicals, a subsidiary of the Sanmar Group based
in Chennai.
Strides,
Invent JV acquires Farma Plus
Strides has recently formed a 50:50 JVC through its wholly
subsidiary Strides Arcolab International, UK and Invent Farma
group's called Plus Farma ehf.
Lupin
receives USFDA approval for Sertraline
Lupin announced that the USFDA has approved the company's
Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride
Tablets, 25 mg, 50 mg and 100 mg.
Dabur
Pharma divests domestic non-oncology business
Dabur Pharma, announced the sale of its domestic non-oncology
formulations business to Alembic.
Acambis
and Bharat Biotech to test JE vaccine
Acambis has commenced a paediatric clinical trial in India
of ChimeriVax-JE, its investigational single-dose vaccine
against Japanese encephalitis.
|
